BMO Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform

April 6, 2016 4:22 PM

BMO Capital initiates coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Outperform rating and a price target of $239.00.Analyst M ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found